Liraglutide suppresses the proliferation of endometrial cancer cells through the adenosine 5'-monophosphate (AMP)-activated protein kinase signaling pathway

Chin Med J (Engl). 2021 Jan 19;134(5):576-578. doi: 10.1097/CM9.0000000000001363.

Authors

Xin-Xin Zhu¹, Zong-Hao Feng², Lin-Zhi Liu¹, Yan Zhang¹

Affiliations

¹ Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing 100034, China.
² Department of Obstetrics and Gynecology, Beijing Tsinghua Changgung Hospital, Beijing 102218, China.

No abstract available

MeSH terms

AMP-Activated Protein Kinases / metabolism
Adenosine
Adenosine Monophosphate
Cell Proliferation
Endometrial Neoplasms* / drug therapy
Female
Humans
Liraglutide*
Phosphorylation
Protein Kinases
Signal Transduction

Substances

Adenosine Monophosphate
Liraglutide
Protein Kinases
AMP-Activated Protein Kinases
Adenosine